Eduovisual
Patient Safety & Systems-Based Practice
Central line bundle and CLABSI prevention
— Central line = catheter terminating at or near the heart/great vessels used for infusion, withdrawal, or hemodynamic monitoring (PICC, tunneled, non-tunneled, implanted port, dialysis catheter, introducer sheath).
— Peripheral IVs and midline catheters are not central lines and do not generate CLABSI events.
— New fever, chills, rigors (especially within minutes of line flush — highly suggestive), hypotension, or unexplained leukocytosis in any patient with an indwelling central catheter.
— Local findings: purulence, erythema, or tenderness at exit site or tunnel tract.
— Catheter dysfunction (sluggish flow) in a febrile patient — biofilm/fibrin sheath may harbor organisms.
— Persistent bacteremia >72 h on appropriate antibiotics, or relapse after stopping antibiotics with line still in place.
Board pearl: A rigor immediately following flush of a central line in an afebrile patient is a classic CLABSI vignette — draw paired cultures (line + peripheral) before empiric vancomycin.
— Hospital day 5+ with central line, new T 38.7°C, no obvious source on exam/CXR/UA.
— Dialysis patient with tunneled catheter presenting from home with fevers and shaking chills during/after dialysis run.
— TPN-dependent short-bowel patient with intermittent fevers and positive Candida blood cultures.
— Post-op ICU patient with introducer sheath in place >4 days developing unexplained leukocytosis and hypotension.
— Line characteristics: type (PICC vs tunneled vs port vs non-tunneled), insertion site (femoral > IJ > subclavian for infection risk), dwell time, number of lumens, who placed it and under what conditions (emergent placements skip full barrier precautions and are higher risk).
— Line use: TPN (Candida, CoNS), blood products, chemotherapy, frequent blood draws (more manipulation = more risk), home infusion (assess caregiver technique).
— Symptom timing relative to line manipulation: rigors within 30 minutes of flush strongly implicate the catheter.
— Prior cultures and antibiotic exposure: prior MRSA/VRE colonization shapes empiric therapy; recent broad-spectrum antibiotics raise candidemia risk.
— Immunocompromise: neutropenia, transplant, steroids, biologics.
— No cough/sputum/infiltrate (rules out pneumonia), no dysuria/pyuria, no abdominal tenderness, no wound drainage, no diarrhea (C. difficile), no new murmur (yet — endocarditis is a late complication).
— Femoral lines in obese or incontinent patients (highest contamination risk).
— Lines placed during cardiac arrest or trauma resuscitation (consider replacement within 48 h under sterile conditions).
Step 3 management: In any patient with a central line and new fever without clear alternative source, draw blood cultures from the line AND a peripheral site simultaneously before antibiotics — differential time-to-positivity ≥2 h in the catheter sample establishes catheter as source.
— Fever (>38°C) is most common but absent in ~30%, especially elderly, uremic, or immunosuppressed patients — use a lower threshold for cultures.
— Tachycardia, hypotension, widened pulse pressure → consider evolving sepsis; activate sepsis bundle (lactate, broad cultures, fluids 30 mL/kg, empiric antibiotics within 1 hour).
— Rigors temporally linked to line flush are a near-pathognomonic finding.
— Inspect exit site for erythema, induration, purulence, or crusting.
— Palpate tunnel tract (tunneled catheters/ports) for tenderness — tunnel infection mandates line removal.
— Assess dressing integrity, date of last change, presence of blood/moisture under dressing.
— Check for leakage, kinking, or partial withdrawal of catheter (measure external length against documented insertion length).
— Cardiac: new murmur → endocarditis (TEE indicated for S. aureus bacteremia or persistent candidemia).
— Skin: Janeway lesions, Osler nodes, splinter hemorrhages, peripheral septic emboli.
— Eyes: Roth spots; fundoscopy mandatory in candidemia to detect endophthalmitis.
— MSK: vertebral or joint tenderness (septic arthritis, discitis, osteomyelitis).
— Pulmonary: crackles, hypoxia → septic pulmonary emboli, especially with right-sided endocarditis or upper-extremity septic thrombophlebitis.
— Extremity: swelling, cord-like palpable vein along catheter path → suppurative thrombophlebitis (surgical emergency).
Key distinction: Exit-site infection (erythema/purulence <2 cm from site, no systemic signs) can sometimes be salvaged with topical/local care; tunnel infection or pocket infection always mandates catheter removal regardless of bacteremia status.
— Draw two sets minimum: one from each lumen of the central catheter AND one from a peripheral venipuncture, all before antibiotics, all time-stamped.
— Volume matters: 20–30 mL per set in adults — low volumes drop sensitivity dramatically.
— Do not draw cultures from a newly placed line in lieu of peripheral — defeats interpretive value.
— Differential time-to-positivity (DTP): catheter culture turning positive ≥120 minutes before peripheral = catheter is the source (sensitivity ~85%, specificity ~90%).
— Quantitative cultures: colony count from catheter ≥3× peripheral count also implicates the line (less commonly available).
— Send 5-cm distal tip for semi-quantitative roll-plate (Maki technique): ≥15 CFU + concordant peripheral blood culture = CLABSI.
— Do not culture tip routinely from removed lines without clinical suspicion (high false-positive rate, drives unnecessary antibiotics).
— CBC with differential (leukocytosis, left shift, or neutropenia), CMP, lactate, procalcitonin (supportive, not diagnostic), CRP.
— Coagulation panel if planning line removal in thrombocytopenic patient.
— Urinalysis, urine culture, CXR, and other site-specific studies to exclude alternative sources — CLABSI is partly a diagnosis of exclusion.
— Persistent bacteremia >72 h on appropriate therapy → TTE, then TEE (sensitivity ~95% vs ~60% for TTE) to evaluate endocarditis or vegetations on catheter.
— Upper-extremity swelling along catheter → duplex ultrasound for septic thrombophlebitis.
— Candidemia → dilated fundoscopic exam within 1 week to exclude endophthalmitis.
Board pearl: A single positive blood culture for coagulase-negative Staphylococcus is usually contamination; require two separate positive cultures with the same organism (and ideally DTP) before treating as true CLABSI. S. aureus, S. lugdunensis, Candida, and gram-negative rods are never considered contaminants — treat any single positive culture.
— TTE first for low pretest probability endocarditis; TEE indicated for: S. aureus bacteremia, persistent bacteremia/fungemia >72 h on therapy, prosthetic valves, intracardiac devices (pacemaker/ICD leads), or non-diagnostic TTE in suspected IE.
— Catheter-tip vegetations on right atrium or SVC junction may be visualized — implies need for line removal and prolonged therapy.
— Duplex ultrasound of the catheter-bearing extremity if local swelling, persistent bacteremia, or S. aureus — diagnoses septic thrombophlebitis (Lemierre-like syndrome of the upper extremity), which mandates line removal, anticoagulation, and 4–6 weeks of antibiotics.
— CT venography if central venous involvement (SVC, brachiocephalic) suspected.
— Mandatory at 48–72 hours after initiation of appropriate therapy in S. aureus, Candida, gram-negative bacteremia, or any CLABSI to document clearance.
— Persistent positivity defines complicated bacteremia → extends treatment duration to 4–6 weeks and intensifies workup.
— MRI spine if back pain (vertebral osteomyelitis/epidural abscess).
— Joint aspiration if effusion.
— Abdominal imaging for splenic/hepatic abscess.
— Dilated ophthalmologic exam for candidemia (endophthalmitis treatment differs).
— β-D-glucan, T2Candida panel — adjuncts for invasive candidiasis when cultures lag.
— MALDI-TOF and rapid PCR (Verigene, FilmArray BCID) shorten time to organism ID and guide de-escalation — supports antimicrobial stewardship metric.
— Guidewire exchange is contraindicated when CLABSI is suspected; the new catheter sits in an infected tract. Acceptable only if line malfunction without infection.
Step 3 management: For S. aureus CLABSI, order: (1) line removal, (2) TEE, (3) repeat blood cultures q48h until clearance, (4) ID consult, (5) minimum 14 days IV antibiotics from first negative culture (4–6 weeks if complicated).
— Use DTP, quantitative cultures, tip cultures, and clinical context. If yes → proceed to removal vs salvage decision.
— Always remove for: severe sepsis/septic shock, hemodynamic instability, endocarditis, suppurative thrombophlebitis, tunnel/pocket infection, persistent bacteremia >72 h on therapy, or infection with S. aureus, P. aeruginosa, Candida species, mycobacteria, or fungi other than Candida.
— Salvage may be attempted (with antibiotic lock therapy) for: uncomplicated CoNS or enteric gram-negative CLABSI in patients who are stable, have limited vascular access (chronic HD, short-bowel TPN), and no metastatic complications.
— In hemodialysis patients with tunneled catheter CLABSI: exchange over guidewire with new tunnel after 48–72 h of negative cultures is acceptable for non-virulent organisms.
— Cover MRSA (vancomycin) in all hospitalized patients with suspected CLABSI.
— Add antipseudomonal gram-negative coverage (cefepime, piperacillin-tazobactam, or meropenem) if neutropenic, septic shock, femoral line, or known multidrug-resistant colonization.
— Add empiric echinocandin (micafungin or caspofungin) if: septic shock + TPN/prolonged broad-spectrum antibiotics, known Candida colonization at multiple sites, hematologic malignancy with neutropenia, or femoral catheterization.
CCS pearl: In the CCS module, the high-yield order set for suspected CLABSI is: blood cultures × 2 from line AND peripheral → start vancomycin + cefepime → consider micafungin if risk factors → remove catheter if patient is unstable, S. aureus, Candida, or pseudomonas → ID consult → advance clock 48 h → repeat cultures → narrow therapy.
— Vancomycin 25–30 mg/kg IV loading dose, then 15–20 mg/kg q8–12h targeting AUC₂₄ 400–600 (preferred over trough-based dosing per 2020 IDSA guidance).
— Daptomycin 8–10 mg/kg/day if vancomycin MIC >2, vancomycin intolerance, or persistent MRSA bacteremia (do not use for pneumonia — inactivated by surfactant).
— Cefepime 2 g IV q8h OR piperacillin-tazobactam 4.5 g q6h OR meropenem 1 g q8h for gram-negative coverage if risk factors above.
— Echinocandin (micafungin 100 mg IV daily, caspofungin 70→50 mg daily) for empiric candidemia coverage.
— Coagulase-negative staph: vancomycin × 5–7 days if catheter removed; 10–14 days if retained with lock therapy.
— MSSA: cefazolin 2 g q8h or nafcillin 2 g q4h × 14 days minimum (uncomplicated, line removed, TEE negative, prompt clearance, no metastatic disease); 4–6 weeks if complicated.
— MRSA: vancomycin × 14 days minimum, 4–6 weeks if complicated.
— Enterococcus: ampicillin (susceptible) or vancomycin × 7–14 days; VRE → daptomycin or linezolid.
— Gram-negative bacilli: β-lactam per susceptibilities × 7–14 days.
— Candida: echinocandin × 14 days from clearance; step-down to fluconazole if susceptible and stable; always remove line; ophtho exam mandatory.
— Instill high-concentration antibiotic (vancomycin 5 mg/mL, gentamicin 1–2 mg/mL, or ethanol 70%) into the lumen between uses for 10–14 days.
— Combined with systemic therapy; reserved for stable patients with limited access.
Board pearl: Cefazolin > vancomycin for MSSA — switching from vancomycin to cefazolin or nafcillin after susceptibilities return reduces mortality. Don't leave a patient on vancomycin for MSSA bacteremia.
1. Hand hygiene before donning sterile attire.
2. Maximal sterile barrier precautions: mask, cap, sterile gown, sterile gloves, full-body sterile drape covering the patient.
3. Chlorhexidine skin antisepsis (>0.5% CHG with alcohol); allow to dry ≥30 seconds (2 min on groin).
4. Optimal site selection: subclavian > internal jugular > femoral for infection risk in adults (balance against pneumothorax risk and operator expertise). Avoid femoral when possible.
5. Daily review of line necessity with prompt removal when no longer needed — single highest-impact intervention.
— Ultrasound guidance for IJ placement (reduces mechanical complications, indirectly reduces infection from repeat attempts).
— Pre-procedure time-out and checklist; empower any team member to halt the procedure for breaks in sterile technique ("stop-the-line" authority).
— Use antimicrobial-impregnated catheters (chlorhexidine/silver-sulfadiazine or minocycline/rifampin) if institutional CLABSI rate remains elevated despite bundle adherence, or in high-risk patients (ICU, expected dwell >5 days).
— Daily CHG bathing for ICU patients with central lines.
— Scrub the hub: disinfect catheter hubs and ports with alcohol or CHG-alcohol for ≥15 seconds before every access.
— Sterile transparent semipermeable dressing changed q7 days or sooner if soiled/loose; CHG-impregnated sponge/disk at exit site.
— Tubing changes: primary continuous sets ≤96 h (not more often than 96 h), blood/lipid sets q24h, propofol q6–12 h.
— Do not routinely replace central catheters to prevent infection.
Step 3 management: A patient still has a central line "because it's there" — the correct order is to remove it today. Daily necessity assessment is the single most tested and highest-yield CLABSI prevention intervention.
— Often present without fever; rely on subtle signs — new confusion, falls, anorexia, hypothermia, or unexplained tachycardia.
— Polypharmacy increases drug interaction risk (vancomycin + loop diuretics → nephrotoxicity; linezolid + SSRIs → serotonin syndrome).
— Skin fragility: gentle dressing removal, consider silicone-based adhesives to prevent skin tears that become contamination sites.
— Goals of care discussion is mandatory when a long-term central line is being placed in a frail elderly patient — line maintenance burden, infection risk, and trajectory should be aligned with patient values.
— Vancomycin requires AUC-guided dosing with pharmacy involvement; in AKI/CKD use loading dose then redose based on level. Avoid trough-only monitoring per 2020 guidelines.
— Aminoglycosides generally avoided; if used for synergy, very short courses.
— Daptomycin dose-adjust for CrCl <30 (q48h). Monitor weekly CPK.
— Piperacillin-tazobactam + vancomycin combination doubles AKI risk vs cefepime + vancomycin — prefer cefepime when feasible.
— Hemodialysis catheter CLABSI: prefer cuffed tunneled catheter exchange or AV access conversion; antibiotic lock therapy is well-validated in this population due to access scarcity.
— Avoid prolonged linezolid (hepatotoxicity, lactic acidosis).
— Echinocandins: caspofungin requires dose reduction in moderate hepatic impairment; micafungin and anidulafungin do not require adjustment.
— Ceftriaxone: caution with biliary sludge in cirrhotic patients on prolonged courses.
Key distinction: In hemodialysis CLABSI, line salvage with lock therapy is more acceptable than in other populations because vascular access is a finite, life-sustaining resource — but S. aureus, Pseudomonas, and Candida still mandate removal.
— Hyperemesis or preeclampsia patients on TPN, or pregnant patients with chronic illness requiring PICCs, are at elevated CLABSI risk.
— Safe in pregnancy: β-lactams (penicillins, cephalosporins, carbapenems), vancomycin, daptomycin (limited data, category B), echinocandins (preferred over fluconazole in 1st trimester — fluconazole is teratogenic at >400 mg/day).
— Avoid: fluoroquinolones (cartilage), tetracyclines (teeth/bone), aminoglycosides (ototoxicity), TMP-SMX in 1st and 3rd trimesters.
— Remove line promptly; involve MFM if systemic illness.
— Most common organisms: CoNS, S. aureus, gram-negatives in neonates; Candida in NICU TPN-dependent infants.
— Bundle adherence is the same; weight-based dosing critical.
— Higher tolerance for line salvage in pediatric oncology given access limitations and complications of repeated central access.
— Ethanol lock therapy is well-studied in pediatric intestinal failure on home TPN — significantly reduces recurrent CLABSI.
— Febrile neutropenia + central line: empirical regimen must cover Pseudomonas (cefepime, pip-tazo, or meropenem) + vancomycin if hemodynamic instability, skin/soft tissue infection, mucositis, or known MRSA colonization.
— Empiric antifungal (echinocandin or voriconazole) after 4–7 days of persistent fever despite broad-spectrum antibiotics.
— Implanted ports often salvageable for uncomplicated CoNS bacteremia; remove for S. aureus, Candida, mycobacteria, tunnel/pocket infection, or persistent bacteremia.
— Lower threshold for line removal; CMV, atypical mycobacteria, and mold infections enter the differential.
— Drug-interaction landmines: voriconazole/posaconazole ↑ tacrolimus/sirolimus levels markedly — reduce CNI doses 50–75% and monitor levels closely.
Board pearl: A neutropenic patient with persistent fever on broad-spectrum antibiotics for >4 days needs empiric antifungal therapy and aggressive search for line/fungal source — including CT chest for invasive aspergillosis and removal of central catheter if Candida is identified.
— S. aureus CLABSI carries 25–32% risk of endocarditis; TEE mandatory.
— Right-sided IE more common from line-related bacteremia; left-sided implies hematogenous seeding and longer therapy.
— Surgical indications: large vegetations >10 mm with embolization, valve dysfunction with heart failure, perivalvular abscess, fungal IE, persistent bacteremia despite appropriate therapy.
— Erythema, swelling, palpable cord along catheter vein; persistent bacteremia despite appropriate antibiotics.
— Treatment: line removal, 4–6 weeks of IV antibiotics, and therapeutic anticoagulation (typically 3 months).
— Surgical thrombectomy/excision rarely needed unless refractory.
— Vertebral osteomyelitis/discitis, septic arthritis, psoas/splenic/renal abscesses, endophthalmitis (Candida), epidural abscess, brain abscess.
— Drives prolonged therapy (often 6+ weeks) and surgical drainage.
Key distinction: Bacteremia clearing within 72 hours of line removal and appropriate antibiotics = uncomplicated (shorter course). Bacteremia persisting beyond 72 hours, metastatic infection, endocarditis, or septic thrombophlebitis = complicated (4–6 weeks IV therapy).
— Septic shock requiring vasopressors (norepinephrine first-line, target MAP ≥65).
— Respiratory failure (septic pulmonary emboli, ARDS).
— Lactate ≥4 mmol/L, persistent altered mental status, or new organ failure.
— Need for central venous access in a patient who just had their infected line removed and is hemodynamically unstable — coordinate timing carefully.
— All S. aureus bacteremia (Level I evidence — reduces mortality ~50%).
— Candidemia.
— Persistent bacteremia >72 h on appropriate therapy.
— Endocarditis, suppurative thrombophlebitis, metastatic infection.
— Catheter salvage decision-making.
— Multidrug-resistant organisms.
— Cardiothoracic/vascular surgery for valve surgery indications or thrombectomy.
— Interventional radiology for new line placement, port removal, or abscess drainage.
— Ophthalmology for candidemia (dilated exam).
— Nephrology for HD-catheter CLABSI and access planning (AV fistula maturation).
— Nutrition for TPN-dependent patients to plan access continuity.
— All CLABSI patients require IV antibiotics; none should be discharged home with a positive blood culture without source control.
— Stable patients with cleared cultures and no complications can complete therapy with outpatient parenteral antimicrobial therapy (OPAT) through a new, non-infected line and home infusion services.
CCS pearl: Order ID consult on day 1 for any suspected S. aureus or Candida CLABSI — this is a scored action item on systems-based practice questions and reflects real-world Level I evidence for mortality reduction.
— Single positive CoNS, diphtheroids, Bacillus (non-anthracis), Cutibacterium acnes, or viridans strep from one set only.
— Repeat cultures to confirm; do not escalate therapy on single positive contaminant.
— Time-to-positivity >24–48 h favors contamination.
— TPN-related fever from contaminated solution (rare, but rigors during infusion) — change bag and tubing, culture remaining solution.
— Transfusion reactions (febrile non-hemolytic, septic from contaminated blood product) — different timing relative to product administration.
Key distinction: CoNS bacteremia requires ≥2 positive cultures from separate venipunctures to call a true infection; a single positive S. aureus, S. lugdunensis, Candida, or gram-negative rod is always treated as real.
— Cough, sputum, hypoxia, infiltrate on imaging, positive sputum/BAL cultures; gram-negatives and S. aureus common.
— Procalcitonin may help differentiate; CLABSI is a diagnosis of exclusion after other sources ruled out.
— Indwelling Foley, pyuria, positive urine culture; E. coli, Klebsiella, Enterococcus, Candida.
— Remove or exchange Foley; treat pathogen-directed.
— Post-op patients: anastomotic leak, abscess, cholecystitis, C. difficile.
— CT abdomen/pelvis with contrast if abdominal exam suggestive.
Step 3 management: Before labeling a fever as CLABSI, work through a structured "rule-out other sources" checklist: CXR, UA + urine culture, wound check, abdominal exam, C. difficile PCR if diarrhea, medication review for drug fever. CLABSI is a diagnosis supported by positive cultures and DTP, not by exclusion alone — but you must rule out competing sources to avoid premature closure.
— Confirm catheter removed (or salvaged with documented lock therapy plan).
— Confirm clearance blood cultures negative ×48 h before transitioning to outpatient therapy.
— TEE and metastatic-infection workup completed if indicated.
— Requires reliable venous access (typically a new PICC placed under full sterile barrier at a separate site after cultures clear).
— Coordinate with home infusion pharmacy, visiting nurse, and OPAT clinic for weekly labs (CBC, BMP, vancomycin levels, CPK for daptomycin, LFTs).
— Patient/caregiver education: hand hygiene, scrub-the-hub technique, dressing care, signs/symptoms of recurrent infection, when to call.
— Document expected end-of-therapy date and follow-up appointment with ID before discharge.
— Uncomplicated CoNS with line removal: 5–7 days.
— Uncomplicated S. aureus: 14 days minimum.
— Complicated S. aureus / endocarditis / septic thrombophlebitis: 4–6 weeks.
— Candidemia: 14 days after clearance; longer for endophthalmitis or endocarditis.
— Gram-negative uncomplicated: 7–14 days.
— Reassess ongoing need for any new central line daily.
— Switch to enteral nutrition when possible (avoid TPN line dependence).
— In HD: pursue AV fistula or graft to liberate from tunneled catheter (fistula-first initiative).
— In oncology: implanted port preferred over external catheter when long-term access needed.
— Home TPN: consider ethanol or taurolidine lock prophylaxis in patients with recurrent CLABSI.
Board pearl: Discharging a patient on IV antibiotics with a central line requires a structured OPAT handoff — ID follow-up appointment, weekly labs, home infusion services, and documented patient education. Missing any of these is a transition-of-care safety gap.
— Daily clinical assessment: temperature trend, hemodynamics, exam of new line site and any prior site.
— Daily CBC and BMP; vancomycin levels per AUC protocol (usually after 24–48 h, then 2–3×/week).
— Repeat blood cultures q48h until two consecutive negatives, then daily until 48 h of negativity is documented (for S. aureus, Candida, persistent bacteremia).
— LFTs weekly on prolonged β-lactams or echinocandins.
— CPK weekly on daptomycin.
— Audiometry if prolonged aminoglycoside use.
— CBC with differential, BMP, LFTs, drug levels, CRP/ESR if osteomyelitis or endocarditis.
— Clinical follow-up by ID at week 1, then every 1–2 weeks until therapy completion.
— Reassess line site weekly; educate patient on emergency contact for any new fever.
— Repeat echocardiogram at end of therapy for endocarditis to document baseline.
— In S. aureus bacteremia, consider follow-up MRI spine if back pain emerged during therapy.
— Vascular access planning visit (e.g., nephrology for AV fistula) within 2–4 weeks.
— Recurrent fever, chills, drainage at line site, or rigors with line flush warrant immediate ER evaluation.
— Hand hygiene before any line manipulation; never submerge dressing under water.
— Report any new dyspnea, chest pain, joint pain, back pain, or visual changes (metastatic complications).
— Adherence to full antibiotic course is essential — partial therapy drives relapse and resistance.
Step 3 management: Schedule the first OPAT follow-up within 7 days of discharge with explicit lab orders and a clear plan for what to do if labs are abnormal — this is the kind of structured transition Step 3 tests under "systems-based practice."
— Discuss alternatives (peripheral IV, midline, oral therapy), risks (infection, thrombosis, pneumothorax, arterial injury, death), and benefits.
— In emergencies, implied consent applies; document the emergent indication.
— Capacity assessment in delirious/encephalopathic patients — involve surrogate decision-maker per state hierarchy.
— CMS classifies CLABSI as a Hospital-Acquired Condition; non-payment for additional cost of treatment.
— Publicly reported on Hospital Compare; affects value-based purchasing and reputation.
— Mandatory NHSN reporting in most states; misclassification (e.g., labeling true CLABSI as mucosal-barrier-injury BSI) is a compliance risk.
— When CLABSI is hospital-acquired, transparent disclosure to patient/family is ethically required (AMA, Joint Commission). Apologize, explain, outline corrective actions; many states have "apology laws" protecting expressions of regret.
— Document conversation in chart.
— Root cause analysis (RCA) for serious CLABSI events; focus on system failures (bundle non-compliance, staffing, training) rather than individual blame.
— Empower nurses and any team member to "stop the line" if sterile technique is breached during insertion — psychological safety is essential.
— Highest-risk handoffs: ICU-to-floor transfer (line necessity may be missed), hospital-to-OPAT (lab follow-up gaps), and shift change.
— Use structured tools (SBAR, I-PASS) and explicit checklists naming each indwelling device.
— Hemodialysis catheter use is higher in Black, Hispanic, and uninsured populations — drives disparate CLABSI rates. Advocate early AV fistula referral.
Board pearl: When a CLABSI is identified, the correct sequence is: treat the patient → disclose the hospital-acquired event to patient/family → file an internal safety event → participate in RCA → implement system change. Concealment or minimization is both unethical and legally hazardous.
Key distinction: CLABSI (laboratory-confirmed BSI in patient with central line, no other source) vs MBI-LCBI (mucosal barrier injury BSI in neutropenic/GVHD patient, specific organisms) — NHSN classification affects reporting and stewardship implications.
— "An ICU resident is about to place a central line under partial drape with mask but no cap or gown..." → Stop the procedure; require full barrier precautions before proceeding. Tests "stop-the-line" authority and bundle elements.
— "Hospital day 7, patient on PO diet, hemodynamically stable, central line still in place because the team forgot..." → Remove the central line today. Single most-tested intervention.
— Febrile patient with central line; new rigors after flush → Draw blood cultures from line and peripheral site before antibiotics, then start empiric vancomycin + cefepime; do not delay antibiotics in septic shock.
— One bottle positive for CoNS, no clinical signs → Repeat cultures; do not treat reflexively. Tests contamination vs true infection logic.
— MRSA bacteremia in patient with PICC → Remove line, vancomycin, TEE, repeat cultures q48h, ID consult, minimum 14 days from clearance.
— TPN-dependent patient with positive Candida cultures → Remove line, start echinocandin, ophtho consult, repeat cultures, 14 days from clearance.
— S. aureus bacteremia still positive at day 5 on vancomycin → Look for endocarditis (TEE), metastatic foci, septic thrombophlebitis; check vancomycin MIC and consider switch to daptomycin.
— Stable patient, CoNS, limited access → Antibiotic lock + systemic therapy with attempt at salvage, or catheter exchange over guidewire after 48–72 h of negative cultures.
— Family asks why patient is on prolonged IV antibiotics → Transparent disclosure, apology, plan for prevention, RCA.
— Stable patient ready for discharge on IV antibiotics → New PICC at separate site, weekly labs ordered, ID follow-up scheduled, patient education documented.
Board pearl: When in doubt on a CLABSI vignette, the safest answers usually are: remove the line, get ID involved, repeat blood cultures, and review insertion-bundle compliance.
CLABSI is preventable through rigorous adherence to the central line insertion and maintenance bundle and daily review of line necessity, and when it occurs, management hinges on prompt source control (catheter removal), pathogen-directed antibiotics from paired blood cultures, and ID-led evaluation for metastatic complications — especially in S. aureus and Candida bacteremia.
High-yield recap bullets:
Step 3 management: Walk into every patient's room with a central line and ask three questions — Do they still need it? Is the dressing intact? When was the last time the team scrubbed the hub? Answering "no/no/don't know" is your cue to act; the line you remove today is the CLABSI that never happens tomorrow.